ONC vs. TECH: BeOne Medicines vs. Bio-Techne Stock Comparison

Company Profile

BeOne Medicines (ONC) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BeOne Medicines (ONC) at 18.40% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

For every dollar of sales, both BeOne Medicines (ONC) at 13.86% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both BeOne Medicines (ONC) at 40.23% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Bio-Techne (TECH) reports EPS growth of 152.17%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.

Both BeOne Medicines (ONC) at 0.35 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

BeOne Medicines (ONC) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both BeOne Medicines (ONC) at 52.17 and Bio-Techne (TECH) at 62.74 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Bio-Techne (TECH) at 5.28 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.

Valuation Metrics